Skip to main content
GenMont logo

GenMont — Investor Relations & Filings

Ticker · 3164 ISIN · TW0003164000 TW Manufacturing
Open in API
Filings indexed 1,619 across all filing types
Latest filing 2016-08-11 Regulatory Filings
Country TW Taiwan
Listing TW 3164

About GenMont

www.genmont.com.tw

GenMont Biotech Inc. specializes in the research, development, and manufacturing of functional probiotics and postbiotics. The company operates advanced fermentation and production platforms for concentrated fermented milk, lactic acid bacteria powders, and functional microorganism strains. Its product portfolio features patented probiotic solutions targeting diverse health areas, including immune modulation, metabolic health, dental hygiene, digestive function, weight management, and pet wellness. Key proprietary strains include L. paracasei 33 and GMNL-32. GenMont leverages its technology platforms and extensive patent portfolio to deliver scientifically-backed health supplements. Beyond its proprietary brands, the company provides original equipment manufacturing (OEM) services, supporting the global market with high-quality probiotic and postbiotic ingredients certified by international standards.

Recent filings

Filing Released Lang Actions
105年第2季大陸投資
Regulatory Filings Classification · 95% confidence The document is a detailed tabular disclosure of investment amounts and related financial figures concerning investments in mainland China by a Taiwanese listed company. It includes specific financial data such as capital amounts, investment methods, cumulative investment amounts, and recognized investment gains or losses for the period. The document is relatively short (1292 characters) and does not appear to be a full financial report but rather a regulatory disclosure of investment information. There is no indication that this is an announcement of a report publication or a certification. The content aligns with regulatory filings related to investment disclosures, which typically fall under the category of Regulatory Filings (RNS) as a fallback for miscellaneous regulatory disclosures that do not fit other specific categories like Annual Report or Interim Report. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2016-08-11 Chinese
105年7月背書保證與資金貸與
Regulatory Filings Classification · 95% confidence The document is a brief financial disclosure from a company named 景岳, providing information about fund lending balances and endorsement guarantees for the current and previous months, with all values being zero. The content is very short (601 characters) and consists mainly of tabular data about financial guarantees and lending, without detailed financial statements or analysis. It does not contain any narrative, management discussion, or comprehensive financial data. It appears to be a regulatory disclosure or compliance update rather than a full report or announcement of a report. Given the brevity and nature of the content, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory disclosures that do not fit other specific categories.
2016-08-10 Chinese
105年7月營業收入
Regulatory Filings Classification · 95% confidence The document is a summary revenue report from a listed company, showing monthly and cumulative net operating revenue figures with comparisons to the previous year. It includes notes on accounting standards (IFRS) and reporting practices. The document length is short (766 characters) and it primarily provides financial summary data without detailed financial statements or management discussion. It does not appear to be a full annual or interim report, nor an earnings release with highlights. It is a regulatory disclosure of financial data, typical of a Regulatory Filing (RNS) in the context of Taiwanese market disclosures. There is no indication it is an announcement of a report publication or a certification. Therefore, the best classification is Regulatory Filings (RNS).
2016-08-10 Chinese
公告本公司105年8月9日董事會通過之重要議案
Regulatory Filings Classification · 95% confidence The document is a short announcement from the company 景岳生物科技股份有限公司 dated 105/08/09 (Taiwan calendar year, equivalent to 2016) stating that the board of directors approved the Q2 financial report. The document does not contain the actual financial data or detailed report but only announces the approval of the Q2 financial report. The length is only 586 characters, which is very short and fits the pattern of an announcement rather than the full interim report. According to the rules, such short announcements that state a report is approved or attached but do not contain substantive financial data should be classified as Regulatory Filings (RNS).
2016-08-09 Chinese
105年07月內部人持股異動(事後)
Director's Dealing Classification · 95% confidence The document consists of detailed tables listing shareholdings of company insiders, including directors, supervisors, and executives, with specific numbers of shares held, changes in holdings, and related information. The content focuses on insider share transactions and holdings rather than financial results, management changes, or other corporate events. There is no indication of a full financial report, earnings release, or meeting materials. The document is a report of personal share transactions and holdings by company directors and executives, which matches the definition of Director's Dealing (DIRS). The document length is sufficient and contains substantive data on insider holdings, not just an announcement or certification.
2016-08-05 Chinese
105年07月董事會成員及持股
Director's Dealing Classification · 95% confidence The document contains detailed tabular data about shareholdings and pledged shares of company insiders, including directors, supervisors, and executives. It lists their share counts, pledged shares, and related percentages. The content focuses on insider shareholdings and pledges rather than financial results, management changes, or meeting materials. There is no indication of a report or announcement of voting results, dividends, or capital changes. The document is a disclosure of insider shareholdings and pledges, which aligns with the category of Director's Dealing (DIRS), as it reports personal share transactions or holdings by company directors and executives. The document length is 2560 characters, which is sufficient for such a detailed disclosure. Therefore, the best classification is DIRS.
2016-08-05 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.